Latest Breaking News On - Can res - Page 1 : comparemela.com

Exact Sciences Corp : The National Institute for Health and Care Excellence (NICE) Recommends Use of Exact Sciences Oncotype DX Test to Help Guide Chemotherapy Decisions for Node-positive Breast Cancer Patients

Exact Sciences Corp : The National Institute for Health and Care Excellence (NICE) Recommends Use of Exact Sciences Oncotype DX Test to Help Guide Chemotherapy Decisions for Node-positive Breast Cancer Patients
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomSimon holtCaroline archerFederico maiardiGenomic health incAmerican society of clinical oncologySciences corporationGallen international breast cancer conferenceSciences on linkedinUnited kingdom national institute for healthEuropean society for medical oncologyNational comprehensive cancer networkSwansea university peony breast care unitNational health serviceExact sciences

EXACT SCIENCES CORP: Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients

Oncotype DX receives highest rating of all multigene tests in the guidelines for quality of evidence and strength of recommendation New guidelines reflect highest level of evidence from independent

United statesRick baehnerStephanie spanosFederico maiardiMegan jonesSciences corpSciences on facebookAmerican society of clinical oncologyPrecision oncology at exact sciencesSciences on twitter exactsciencesExchange commissionPrnewswire exact sciences corpGenomic health incSciences corporationNew england journalAmerican society

Updated ASCO Guidelines Strongly Recommend Use of the Oncotype DX Breast Recurrence Score® Test in Node-Negative and the Majority of Node-Positive Early-Stage Breast Cancer Patients

/PRNewswire/ Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that recommended use of its Oncotype DX Breast.

Rick baehnerExchange commissionSciences corpSciences on facebookGenomic health incPrecision oncology at exact sciencesSciences on twitter exactsciencesSciences corporationPrecision oncologyNew england journalRecurrence scorePan cancer tissueExact sciencesGenomic healthRisk factorsAnnual report

Exact Sciences Corp : Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX Test

- RxPONDER, an independent study led by SWOG Cancer Research Network, demonstrates that guiding treatment with Oncotype DX test can spare chemotherapy use in majority of postmenopausal women -

United statesSaudi arabiaSouth koreaKevin kalinskyRick baehnerStephanie spanosFederico maiardiMegan jonesSciences on facebookNational cancer instituteNational comprehensive cancer network incPrecision oncology at exact sciencesWinship cancer institute of emory universityGenomic health incCancer research networkNational comprehensive cancer network

Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX® Test

/PRNewswire/ Exact Sciences Corp. (NASDAQ: EXAS) today announced that data from the Rx for Positive Node, Endocrine Responsive Breast Cancer, or RxPONDER,.

United statesSaudi arabiaSouth koreaKevin kalinskyRick baehnerStephanie spanosFederico maiardiMegan jonesSciences corpSciences on facebookNational comprehensive cancer network incPrecision oncology at exact sciencesSciences on twitter exactsciencesWinship cancer institute of emory universityGlenn family breast centerExchange commission